Zydus Lifesciences Limited has formally announced the superannuation of a key senior management personnel, marking a significant leadership transition within the pharmaceutical company. The announcement pertains to Mr. Manoj Kumar Kamra, who served as Senior Vice President-Corporate Affairs, and represents part of the company's ongoing compliance with regulatory disclosure requirements.

Superannuation Details

The company disclosed that Mr. Manoj Kumar Kamra has superannuated from his position as Senior Vice President-Corporate Affairs, with the cessation taking effect from the closing working hours of January 31, 2026. The superannuation represents a natural conclusion to his tenure in the senior management role.

Regulatory Compliance

The announcement was made in strict adherence to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also references SEBI circulars dated November 11, 2024, and December 31, 2024, ensuring full compliance with the latest regulatory guidelines for senior management changes.

The formal communication was filed with both major stock exchanges where the company's shares are listed:

• BSE Limited (Code: 532321)
• National Stock Exchange of India Limited (Code: Zyduslife)

Corporate Governance

The disclosure was officially signed and submitted by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), on January 31, 2026. The digital signature timestamp shows 16:59:37 +05'30', demonstrating the company's commitment to timely regulatory reporting.

The announcement includes comprehensive annexure details as required under the listing regulations, providing transparency regarding the nature and timing of the senior management change. This structured approach reflects the company's adherence to corporate governance standards and regulatory compliance protocols.

Zydus Lifesciences Limited has officially notified stock exchanges about its upcoming Board of Directors meeting scheduled for February 9, 2026. The pharmaceutical company issued the notice on January 27, 2026, in compliance with regulatory requirements under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The Board of Directors meeting will be held on Monday, February 9, 2026, with the primary agenda being the consideration and approval of unaudited financial results. The meeting will focus on reviewing the company's performance for the quarter and nine months ended December 31, 2025, representing the third quarter of fiscal year 2026.

Trading Window Restrictions

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, Zydus Lifesciences has implemented mandatory trading window restrictions. The trading window will remain closed for all Directors and Designated Persons of the company until Wednesday, February 11, 2026. Normal trading activities will resume on Thursday, February 12, 2026.

Corporate Communication

The official notice was signed by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), and submitted to both major stock exchanges where the company is listed. The communication was addressed to BSE Limited (Code: 532321) and National Stock Exchange of India Limited (Code: Zyduslife), ensuring compliance with dual listing requirements.

The company maintains its registered office at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), near Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. This board meeting announcement follows standard corporate governance practices for publicly listed pharmaceutical companies in India.